Cardiovascular safety of biologic therapies for the treatment of RA. (Q37956137)

25 August 2017

Cardiovascular safety of biologic therapies for the treatment of RA. (English)

1 reference

25 August 2017

1 reference

Jeffrey D Greenberg

1

1 reference

25 August 2017

Victoria Furer

series ordinal

2

1 reference

25 August 2017

Michael E Farkouh

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

15 November 2011

1 reference

Nature Reviews Rheumatology

25 August 2017

1 reference

25 August 2017

8

1 reference

25 August 2017

13-21

1 reference

25 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2011.168

25 August 2017

0 references

cites work

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Patterns of cardiovascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Predicting mortality in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Autoantibodies and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Effect of rheumatoid factor on mortality and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The role of immune complexes in atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Role of inflammation in atherosclerosis associated with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Arterial stiffness in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Methotrexate--how does it really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Tumour necrosis factor alpha in severe congestive cardiac failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving st

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Cardiovascular death in rheumatoid arthritis: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Inverse association between obesity and antinuclear antibodies in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Association of HLA shared epitope with joint damage progression in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Antirheumatic drug use and the risk of acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.168

Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis

31 March 2020

1 reference

12 December 2020

Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset

1 reference

12 December 2020

A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis

1 reference

12 December 2020

Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.

1 reference

12 December 2020

Mortality trends in rheumatoid arthritis: the role of rheumatoid factor

1 reference

12 December 2020

Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis

1 reference

12 December 2020

Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness

1 reference

12 December 2020

Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis

1 reference

12 December 2020

Prediction of mortality in rheumatoid arthritis based on disease activity markers

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2011.168

1 reference

25 August 2017

1 reference